WuXi Biologics, a global company with leading open access biologics technology platforms, announced that it has acquired a Bayer manufacturing facility in Wuppertal, Germany, which has completed Pfizer China (Pfizer) manufacturing facilities in Hangzhou, China and the CMAB Biopharma Group (CMAB).
As part of the acquisition agreement signed with Bayer in December 2020, WuXi Biologics has taken over the operation and assets of an active ingredient plant (MFG19) in Wuppertal, which comprises 3 x 1,000L perfusion and 6 x 2,000L fed-batch capacities with independent downstream suites becomes.
As announced in March 2021, WuXi Biologics completed the acquisition of the Biological Ingredients and Products (MFG20 / DP9 / DP10) facilities from Pfizer China in Hangzhou with 2 x 2,000L disposable bioreactors, which will be expanded to 4 x 2,000L can. There are also two state-of-the-art production facilities for the manufacture of drugs (DP), the formulation of drugs and the filling into vials and syringes.
Also in March 2021, the acquisition of CMAB, a contract development and production organization (CDMO) for biologics based in Suzhou, China, was announced . The CDMO plant maintains systems (MFG21 / DP11) with 7,000 liters of bioreactor DS capacity as well as a DP production facility for liquid and lyophilization filling. WuXi Biologics acquired 100% of the shares in CMAB, which is renamed WuXi Biologics (Suzhou) and operated as a wholly-owned subsidiary.
It is expected that all of these acquired facilities will be ready for GMP production in 2021, expanding WuXi Biologics’ global footprint. With these expansions, the total capacity of the company’s 11 DS systems in China , the USA and Germany will be increased to 150,000 liters by the end of 2021. In addition, there will be nine GMP-DP vial and syringe lines in China , USA and Germany this year to meet all customer needs.
Dr. Chris Chen , CEO of WuXi Biologics, commented, “We are pleased to have signed these significant contracts with Bayer, Pfizer and the CBC Group and welcome the highly skilled talent to our WuXi Biologics family. Over the past ten years, we have continued to expand our capacities and capabilities to build a global biologics network while strengthening the local supply chain to meet the growing biologics outsourcing requirements. With a total of 33 planned DS and DP systems in five countries around the world, we will continue to manufacture high-quality biologics and deliver them promptly worldwide for the benefit of patients thanks to our robust production capacities and resilient supply chains. “
WuXi Biologics, a Hong Kong-listed company, is a leading global open access technology platform for biologics. It provides complete solutions that enable organizations to research, develop, and manufacture biologics from concept to commercial manufacture.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.